HRSA orders Boehringer Ingelheim to comply with 340B drug pricing

The Health Resources andServices Administration (HRSA) has sent a letter to Boehringer Ingelheim ordering the pharmaceutical company to comply with federal requirements under the 340B drug pricing program. 

Read the full post at News Feed
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive